Financial constraints are another major limitation. The cost of developing new treatments, conducting clinical trials, and implementing advanced diagnostic tools can be prohibitively high. Furthermore, ethical considerations often arise, particularly around the use of experimental treatments and the equitable distribution of healthcare resources. Balancing the need for innovation with ethical and financial feasibility remains a significant challenge.